An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

Cancer immunotherapy by targeting of immune checkpoint molecules has been a research ‘hot-spot' in recent years. Nivolumab, a human monoclonal antibody targeting PD-1, has been widely used clinically since 2014. However, the binding mechanism of nivolumab to PD-1 has not yet been shown, despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Shuguang, Zhang, Hao, Chai, Yan, Song, Hao, Tong, Zhou, Wang, Qihui, Qi, Jianxun, Wong, Gary, Zhu, Xiaodong, Liu, William J., Gao, Shan, Wang, Zhongfu, Shi, Yi, Yang, Fuquan, Gao, George F., Yan, Jinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303876/
https://www.ncbi.nlm.nih.gov/pubmed/28165004
http://dx.doi.org/10.1038/ncomms14369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303876/
https://www.ncbi.nlm.nih.gov/pubmed/28165004
http://dx.doi.org/10.1038/ncomms14369

Ejemplares similares